The needle-free lane
The product is described as a topical spray therapy delivering tirzepatide, using a delivery technology the page attributes by name to a separate company. It is priced with a from figure carried to the cent.
Very little of this roster offers anything but an injection. A handful publish an oral dissolving tablet or a sublingual, and this is the only spray presentation we have found. Whether it works as well as an injection is a clinical question this site does not answer and the seller does not evidence; what we can record is that the presentation exists and carries a published price.
Naming the technology is not naming the pharmacy
The page names the company that developed, owns and controls the spray technology, which is more attribution than most product pages carry. It does not name the compounding pharmacy that prepares the drug into it, and those are different facts about different companies.
One hundred and twenty-six of the one hundred and fifty-eight sellers here name no compounding pharmacy, and this is one of them. Seventy-six of the one hundred and fifty-eight name nobody who prescribes; this is one of those too.
Three prices, no terms
The related-products rail on the same page prices a compounded semaglutide and an injectable dual-agonist tirzepatide with B12 at the same figure as each other. That is worth a moment: on almost every other seller here, tirzepatide costs more than semaglutide, sometimes considerably. This one charges the same for both in its injectable lanes and charges a premium only for the spray.
None of the three figures carries a plan term. A first-time coupon code sits on the product page offering a stated amount off a first order, so the first figure a new buyer pays is not the published one. No service area is listed; one hundred and fifteen of the one hundred and fifty-eight sellers here publish none.
ARSYNL Rx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (compounded) | $256.33/mofrom, per month, for the needle-free HypoSpray presentation | September 2026source |
| Tirzepatide (compounded) | $233/mofrom, per month, for the injectable dual-agonist lane | September 2026source |
| Semaglutide (compounded) | $233/mofrom, per month; the seller prices its semaglutide and its injectable tirzepatide at the same figure | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See ARSYNL Rx's current price →Good fit if
- Buyers who want a tirzepatide presentation that does not involve a needle and want it priced before an intake.
- Readers comparing a semaglutide lane against an injectable tirzepatide lane priced identically by the same seller.
Look elsewhere if
- Anyone who needs a plan term stated beside a price. None of the three figures carries one.
- Readers who want the compounding pharmacy named; only the delivery-technology owner is.
- Buyers who need a service-area list, a named clinician, or an answer on membership.
- People who would rather not have a coupon code between them and the published price.
How this review was verified
- Re-read the HypoSpray product page and the privacy policy on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Took all three figures from the product page and its related-products rail as joined text nodes, including the one carried to the cent.
- Recorded the delivery-technology owner as the technology owner rather than as a pharmacy, because they are different disclosures.
- Recorded the first-order coupon as a condition on the published figure rather than treating the discounted amount as a price.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched.